MedTrace Logo

Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases

NCT04213222 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2020-08-11

No results posted yet for this study

Summary

Colorectal carcinoma with liver metastasis is one of the major problems bothering physicians worldwide. Bevacizumab combined with chemotherapy is the standard treatment recommended by several guidelines. Despite the high cost, a certain portion of patients couldn't benefit from this therapy. This study is aiming to find out the specific type of patients who would respond to bevacizumab by Radiomics approach, and evaluate the prediction value of this imaging model with clinical and genetic factors.

Conditions

Interventions

DRUG

Bevacizumab

bevacizumab combined with chemotherapy

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2022-06-30
Completion
2023-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04213222 on ClinicalTrials.gov